These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31558067)

  • 1. Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with
    Fazio F; Barberi W; Cazzaniga G; Fazio G; Messina M; Della Starza I; De Propris MS; Mancini F; Mohamed S; Del Giudice I; Chiaretti S; Moleti ML; Guarini A; Foà R; Testi AM
    Leuk Lymphoma; 2020 Feb; 61(2):469-472. PubMed ID: 31558067
    [No Abstract]   [Full Text] [Related]  

  • 2. Effective treatment with imatinib for acute B-lymphoblastic leukaemia with EBF1-PDGFRB fusion.
    Horiuchi M; Yoshida M; Yamasaki K; Sakagami R; Aoyama T; Tatsumi N; Tsutsumi M; Nakaya Y; Fuseya H; Yoshimura T; Hayashi Y; Nakao T; Yamane T
    Ann Hematol; 2021 May; 100(5):1329-1331. PubMed ID: 33150465
    [No Abstract]   [Full Text] [Related]  

  • 3. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.
    Schwab C; Ryan SL; Chilton L; Elliott A; Murray J; Richardson S; Wragg C; Moppett J; Cummins M; Tunstall O; Parker CA; Saha V; Goulden N; Vora A; Moorman AV; Harrison CJ
    Blood; 2016 May; 127(18):2214-8. PubMed ID: 26872634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute lymphoblastic leukemia with EBF1-PDGFRB fusion gene: two cases report and literature review].
    Chen YQ; Zheng YZ; Li J; Hua XL; Le SH
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):69-71. PubMed ID: 36987727
    [No Abstract]   [Full Text] [Related]  

  • 5. B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review.
    Sakurai Y; Sarashina T; Toriumi N; Hatakeyama N; Kanayama T; Imamura T; Osumi T; Ohki K; Kiyokawa N; Azuma H
    J Pediatr Hematol Oncol; 2021 Jan; 43(1):e105-e108. PubMed ID: 32068648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.
    Bielorai B; Leitner M; Goldstein G; Mehrian-Shai R; Trakhtenbrot L; Fisher T; Marcu V; Yalon M; Schiby G; Barel O; Cal N; Golan H; Toren A
    Acta Haematol; 2019; 141(2):119-127. PubMed ID: 30726835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early diagnosis of EBF1-PDGFRB-positive acute lymphoblastic leukemia.
    Ishihara T; Watakabe M; Ochi S; Akisada N; Nogami K
    Pediatr Int; 2022 Jan; 64(1):e14955. PubMed ID: 35289450
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.
    Zhang G; Zhang Y; Wu J; Chen Y; Ma Z
    Am J Case Rep; 2017 Nov; 18():1204-1208. PubMed ID: 29133777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATF7IP as a novel PDGFRB fusion partner in acute lymphoblastic leukaemia in children.
    Kobayashi K; Mitsui K; Ichikawa H; Nakabayashi K; Matsuoka M; Kojima Y; Takahashi H; Iijima K; Ootsubo K; Oboki K; Okita H; Yasuda K; Sakamoto H; Hata K; Yoshida T; Matsumoto K; Kiyokawa N; Ohara A
    Br J Haematol; 2014 Jun; 165(6):836-41. PubMed ID: 24628626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.
    Lengline E; Beldjord K; Dombret H; Soulier J; Boissel N; Clappier E
    Haematologica; 2013 Nov; 98(11):e146-8. PubMed ID: 24186319
    [No Abstract]   [Full Text] [Related]  

  • 11. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
    Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
    Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis.
    Welsh SJ; Churchman ML; Togni M; Mullighan CG; Hagman J
    Leukemia; 2018 Jan; 32(1):38-48. PubMed ID: 28555080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB/STAT5 signalling pathways and sensitivity to TKI in ph-like ALL.
    Xu GF; Zeng Z; Zhang ZB; Zhang XM; Wang M; Xiao Q; Li J; Xie XQ; He S; Fu HH; Liu Y; Yang ZL; Chen Y; Shi J; Wang B; Qiu HY; Zhou Q; Liu Y; Chen SN
    J Cell Mol Med; 2024 Feb; 28(3):e18114. PubMed ID: 38323741
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Zhang Y; Gao Y; Zhang H; Zhang J; He F; Hnízda A; Qian M; Liu X; Gocho Y; Pui CH; Cheng T; Wang Q; Yang JJ; Zhu X; Liu X
    Blood; 2018 May; 131(20):2256-2261. PubMed ID: 29434033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate.
    Zou YS; Hoppman NL; Singh ZN; Sawhney S; Kotiah SD; Baer MR
    Cancer Genet; 2017 Apr; 212-213():38-44. PubMed ID: 28449810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of Bone Marrow Necrosis by Tyrosine Kinase Inhibitor Substitution in a Pediatric Patient With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
    Mikami T; Kato I; Oiki N; Okamoto S; Kamitori T; Tasaka K; Ogata H; Tanaka K; Umeda K; Hiramatsu H; Okamoto T; Adachi S; Takita J
    J Pediatr Hematol Oncol; 2022 Mar; 44(2):e539-e542. PubMed ID: 33843813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
    Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
    Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in pregnancy.
    Mainor CB; Duffy AP; Atkins KL; Kimball AS; Baer MR
    J Oncol Pharm Pract; 2016 Apr; 22(2):374-7. PubMed ID: 25616656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.
    Weston BW; Hayden MA; Roberts KG; Bowyer S; Hsu J; Fedoriw G; Rao KW; Mullighan CG
    J Clin Oncol; 2013 Sep; 31(25):e413-6. PubMed ID: 23835704
    [No Abstract]   [Full Text] [Related]  

  • 20. Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia.
    Shimomura Y; Maruoka H; Ishikawa T
    Int J Hematol; 2017 May; 105(5):697-701. PubMed ID: 28000100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.